Clinical Research Directory
Browse clinical research sites, groups, and studies.
Lemborexant for Cannabis Use Disorder
Sponsor: University of Calgary
Summary
The goal of this clinical trial is to investigate the use of Lemborexant as a treatment for moderate to severe Cannabis Use Disorder (CUD). The main questions it aims to answer are: 1. Is Lemborexant safe, feasible, and tolerable to use in the CUD population? 2. Will the use of Lemborexant for CUD help to decrease cannabis use, improve sleep, decrease cannabis withdrawal symptoms, and improve cognition? Researchers will compare 10mg Lemborexant to placebo. Participants will: * Take 10mg Lemborexant (or placebo) nightly for 21 nights (treatment phase). * Wear an actigraphy watch continuously for the treatment phase. * Complete a pre-screen survey, attend an in-person screening session, 4 in-person lab visits (weekly from days 0-21), and a virtual follow-up visit 2 weeks after the treatment phase. * Complete a short daily survey for 35 days total.
Official title: Lemborexant as a Potential Pharmacotherapy for the Treatment of Cannabis Use Disorder (CUD)
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
28
Start Date
2026-11
Completion Date
2028-11
Last Updated
2026-09-03
Healthy Volunteers
No
Conditions
Interventions
Lemborexant 10mg
21 days of 10mg Lemborexant, taken nightly.
Placebo
21 days of visually-matched placebo, taken nightly.
Brief Behavioural Intervention
Participants will receive a brief behavioural intervention at the in-person study visits aimed at helping participants identify ways to reduce their cannabis use.
Locations (1)
University of Calgary (Foothills Campus)
Calgary, Alberta, Canada